In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8+ T cell response and advancement of epitope based immunotherapy for CHIKV infection

Infection, Genetics and Evolution

Volumn 31, Issue , 2015, Pages 118-126

  Pratheek, B M ^a   Suryawanshi, Amol R ^b   Chattopadhyay, Soma ^b   Chattopadhyay, Subhasis ^a  

^a NATIONAL INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Chikungunya virus; H2 Db; H2 Dd; HLA I; MHC I epitope

Indexed keywords

CHIKUNGUNYA VIRUS PROTEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; H2 ANTIGEN; HLA ANTIGEN CLASS 1;

ALLELE; ARTICLE; BINDING AFFINITY; BINDING SITE; CD8+ T LYMPHOCYTE; CHIKUNGUNYA; GENE SEQUENCE; HAPLOTYPE; IMMUNE RESPONSE; IMMUNOGENICITY; MATHEMATICAL MODEL; PREDICTION; PROTEIN BINDING; VALIDATION PROCESS; AMINO ACID SEQUENCE; ANIMAL; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; EPITOPE MAPPING; FACTUAL DATABASE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR DOCKING; MOUSE; NUCLEOTIDE SEQUENCE; PROCEDURES; PROTEIN CONFORMATION; VIROLOGY;

ALPHAVIRUS; CHIKUNGUNYA VIRUS;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; DATABASES, FACTUAL; EPITOPE MAPPING; EPITOPES; EPITOPES, T-LYMPHOCYTE; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; MICE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; VIRAL PROTEINS;

EID: 84922463844     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2015.01.017     Document Type: Article

References (56)

1. Accelrys-Software-Inc. Discovery Studio Visualizer 2013, Accelrys Software Inc.: Discovery Studio Modeling Environment, San Diego. 4th ed.
2. Arnon R., Horwitz R.J. Synthetic peptides as vaccines. Curr. Opin. Immunol. 1992, 4:449-453.
3. Bao H., Ramanathan A.A., Kawalakar O., Sundaram S.G., Tingey C., Bian C.B., Muruganandam N., Vijayachari P., Sardesai N.Y., Weiner D.B., Ugen K.E., Muthumani K. Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral Immunol. 2013, 26:75-83.
4. Bergmann C.C., Yao Q., Lin M., Stohlman S.A. The JHM strain of mouse hepatitis virus induces a spike protein-specific Db-restricted cytotoxic T cell response. J. Gen. Virol. 1996, 77(Pt 2):315-325.
5. Brown F. New approaches to vaccination against foot-and-mouth disease. Vaccine 1992, 10:1022-1026.
6. Cao K., Hollenbach J., Shi X., Shi W., Chopek M., Fernandez-Vina M.A. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 2001, 62:1009-1030.
7. Chattopadhyay S., Chakraborty N.G. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum. Immunol. 2005, 66:884-891.
8. Chattopadhyay S., Mehrotra S., Chhabra A., Hegde U., Mukherji B., Chakraborty N.G. Effect of CD4+ CD25+ and CD4+ CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. J. Immunol. 2006, 176:984-990.
9. Chua C.L., Chan Y.F., Sam I.C. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein. J. Virol. Methods 2014, 195:126-133.
10. Comeau S.R., Kozakov D., Brenke R., Shen Y., Beglov D., Vajda S. ClusPro: performance in CAPRI rounds 6-11 and the new server. Proteins 2007, 69:781-785.
11. Crooks G.E., Hon G., Chandonia J.M., Brenner S.E. WebLogo: a sequence logo generator. Genome Res. 2004, 14:1188-1190.
12. Dethlefs S., Escriou N., Brahic M., van der Werf S., Larsson-Sciard E.L. Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice. J. Virol. 1997, 71:5361-5365.
13. Eisenberg D., Schwarz E., Komaromy M., Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 1984, 179:125-142.
14. Fan C.F., Mei X.G. Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response. Vaccine 2005, 23:4453-4461.
15. Fan C.F., Zeng R.H., Sun C.Y., Mei X.G., Wang Y.F., Liu Y. Fusion of DsbA to the N-terminus of CTL chimeric epitope, F/M2:81-95, of respiratory syncytial virus prolongs protein- and virus-specific CTL responses in Balb/c mice. Vaccine 2005, 23:2869-2875.
16. Francini G., Scardino A., Kosmatopoulos K., Lemonnier F.A., Campoccia G., Sabatino M., Pozzessere D., Petrioli R., Lozzi L., Neri P., Fanetti G., Cusi M.G., Correale P. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 2002, 169:4840-4849.
17. Gonser S., Weber E., Folkers G. Peptides and polypeptides as modulators of the immune response: thymopentin - an example with unknown mode of action. Pharm. Acta Helv. 1999, 73:265-273.
18. Griffin D. Alphaviruses. Fields Virology 2007, 1023-1068. Lippincott-Williams & Wilkins, Philadelphia. fivth ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
19. Hallengard D., Kakoulidou M., Lulla A., Kummerer B.M., Johansson D.X., Mutso M., Lulla V., Fazakerley J.K., Roques P., Le Grand R., Merits A., Liljestrom P. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J. Virol. 2014, 88:2858-2866.
20. Hansen T.H., Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat. Rev. Immunol. 2009, 9:503-513.
21. Hiasa Y., Takahashi H., Shimizu M., Nuriya H., Tsukiyama-Kohara K., Tanaka T., Horiike N., Onji M., Kohara M. Major histocompatibility complex class-I presentation impaired in transgenic mice expressing hepatitis C virus structural proteins during dendritic cell maturation. J. Med. Virol. 2004, 74:253-261.
22. Hoarau J.J., Gay F., Pelle O., Samri A., Jaffar-Bandjee M.C., Gasque P., Autran B. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island. PLoS One 2013, 8:e84695.
23. Hoof I., Peters B., Sidney J., Pedersen L.E., Sette A., Lund O., Buus S., Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009, 61:1-13.
24. Kim Y., Ponomarenko J., Zhu Z., Tamang D., Wang P., Greenbaum J., Lundegaard C., Sette A., Lund O., Bourne P.E., Nielsen M., Peters B. Immune epitope database analysis resource. Nucleic Acids Res. 2012, 40:W525-530.
25. Kim Y., Sidney J., Pinilla C., Sette A., Peters B. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinform. 2009, 10:394.
26. Kozakov D., Brenke R., Comeau S.R., Vajda S. PIPER: an FFT-based protein docking program with pairwise potentials. Proteins 2006, 65:392-406.
27. Kumar S., Jaffar-Bandjee M.C., Giry C., Connen de Kerillis L., Merits A., Gasque P., Hoarau J.J. Mouse macrophage innate immune response to Chikungunya virus infection. Virol. J. 2012, 9:313.
28. Maciel M., Kellathur S.N., Chikhlikar P., Dhalia R., Sidney J., Sette A., August T.J., Marques E.T. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 2008, 378:105-117.
29. Metz S.W., Martina B.E., van den Doel P., Geertsema C., Osterhaus A.D., Vlak J.M., Pijlman G.P. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013, 31:6092-6096.
30. Momany F.A., Rone R. Validation of the general purpose QUANTA 3.2/CHARMm force field. J. Comput. Chem. 1992, 13:888.
31. Parida R., Shaila M.S., Mukherjee S., Chandra N.R., Nayak R. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential. Vaccine 2007, 25:7530-7539.
32. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994, 152:163-175.
33. Parola P., de Lamballerie X., Jourdan J., Rovery C., Vaillant V., Minodier P., Brouqui P., Flahault A., Raoult D., Charrel R.N. Novel Chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg. Infect. Dis. 2006, 12:1493-1499.
34. Pewe L., Perlman S. Immune response to the immunodominant epitope of mouse hepatitis virus is polyclonal, but functionally monospecific in C57Bl/6 mice. Virology 1999, 255:106-116.
35. Pratheek B.M., Saha S., Maiti P.K., Chattopadhyay S. Immune regulation and evasion of Mammalian host cell immunity during viral infection. Indian J. Virol. 2013, 24:1-15.
36. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
37. Reche P.A., Glutting J.P., Zhang H., Reinherz E.L. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004, 56:405-419.
38. Reche P.A., Reinherz E.L. PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res. 2005, 33:W138-142.
39. Roh S., Lee Y.K., Ahn B.Y., Kim K., Moon A. Induction of CTL responses and identification of a novel epitope of hepatitis B virus surface antigens in C57BL/6 mice immunized with recombinant vaccinia viruses. Virus Res. 2001, 73:17-26.
40. Ross R.W. A laboratory technique for studying the insect transmission of animal viruses, employing a bat-wing membrane, demonstrated with two African viruses. J. Hyg. (Lond) 1956, 54:192-200.
41. Sahu A., Das B., Das M., Patra A., Biswal S., Kar S.K., Hazra R.K. Genetic characterization of E2 region of Chikungunya virus circulating in Odisha, Eastern India from 2010 to 2011. Infect Genet. Evol. 2013, 18:113-124.
42. Sanchez-Burgos G., Ramos-Castaneda J., Cedillo-Rivera R., Dumonteil E. Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis. Virus Res. 2010, 153:113-120.
43. Schipper R.F., van Els C.A., D'Amaro J., Oudshoorn M. Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. Hum. Immunol. 1996, 51:95-98.
44. Schrödinger, L., 2010 The PyMOL molecular graphics system, Version 1.3r1, Version 1.3r1 ed.
45. Sette A., Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 2003, 15:461-470.
46. Shehzadi A., Ur Rehman S., Idrees M. Promiscuous prediction and conservancy analysis of CTL binding epitopes of HCV 3a viral proteome from Punjab Pakistan: an in silico approach. Virol. J. 2011, 8:55.
47. Sreekumar E., Issac A., Nair S., Hariharan R., Janki M.B., Arathy D.S., Regu R., Mathew T., Anoop M., Niyas K.P., Pillai M.R. Genetic characterization of 2006-2008 isolates of Chikungunya virus from Kerala, South India, by whole genome sequence analysis. Virus Genes 2010, 40:14-27.
48. Strauss J.H., Strauss E.G. The Alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 1994, 58:491-562.
49. Su C.T., Schonbach C., Kwoh C.K. Molecular docking analysis of 2009-H1N1 and 2004-H5N1 influenza virus HLA-B*4405-restricted HA epitope candidates: implications for TCR cross-recognition and vaccine development. BMC Bioinform. 2013, 14(Suppl. 2):S21.
50. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
51. Tong J.C., Simarmata D., Lin R.T., Renia L., Ng L.F. HLA class I restriction as a possible driving force for Chikungunya evolution. PLoS ONE 2010, 5:e9291.
52. Tung C.W., Ho S.Y. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties. Bioinformatics 2007, 23:942-949.
53. Vignuzzi M., Gerbaud S., van der Werf S., Escriou N. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 2001, 82:1737-1747.
54. Wallace M.E., Keating R., Heath W.R., Carbone F.R. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J. Virol. 1999, 73:7619-7626.
55. Wauquier N., Becquart P., Nkoghe D., Padilla C., Ndjoyi-Mbiguino A., Leroy E.M. The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J. Infect. Dis. 2011, 204:115-123.
56. Wilson J.A., Hart M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 2001, 75:2660-2664.